Coexistent adverse cytogenetic lesions shorten survival in myeloma patients with hyperdiploidy. (A-B) Patients with hyperdiploidy alone have a longer PFS and OS than patients with hyperdiploidy plus any adverse cytogenetic lesion. Kaplan-Meier survival curves demonstrate shorter survival for those patients with the presence of any adverse cytogenetic lesion. (A) PFS medians: 15.4 months for patients with the presence of any adverse lesion (n = 195) and 23 months for those without (n = 304); log-rank P < .001. (B) OS medians: 35.7 months vs 60.9 months; log-rank P < .001. (C-E) Coexistence of each adverse cytogenetic lesion with hyperdiploidy results in shorter OS. Kaplan-Meier survival analysis with log-rank P values are shown for patients with hyperdiploidy alone (median OS, 60.9 months) vs (C) patients with hyperdiploidy plus an adverse translocation (median OS, 27 months); (D) patients with hyperdiploidy plus del17p (median OS, 29.9 months); or (E) patients with hyperdiploidy plus +1q (median OS, 35.1 months). HRD, hyperdiploidy.